During Wednesday’s Morning trade, Shares of SunEdison, Inc. (NYSE:SUNE), surged 8.94% to $3.29.
SunEdison’s 1-year price target is estimated as $19.53. The stock opened trading at $3.07, and is floating in a range of $2.71 - $3.60. The stock also hit its lowest level, making 52-week range as $2.71 - $33.45. The total volume traded by the stock is 125,157,274. This is unusual surge in its volume as its average daily volume is 39,198,100 shares. The stock holds the market capitalization of $1.05B. Its beta value is $3.97609.
SunEdison, Inc. develops, manufactures, and sells silicon wafers to the semiconductor industry. The company operates through three segments: Solar Energy, TerraForm Power, and Semiconductor Materials. The Solar Energy segment provides solar energy services that integrate the design, installation, financing, monitoring, operations, and maintenance portions of the downstream solar market. It also manufactures polysilicon, silicon wafers, and solar modules.
Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL), skyrocketed 72.53% to $5.56, during its current trading session, after the company declared that it was preparing regulatory filings for its Alzheimer’s treatment.
Anavex is moving forward with developing its Alzheimer’s treatment based on guidance from the U.S. Food and Drug Administration.
The FDA guidance confirms the company’s strategy to advance its treatment in a larger double-blinded, placebo-controlled Phase 2/3 trial, Anavex said in a statement.
“Working with a highly vulnerable patient population, the Company is proceeding in a rational, step-wise process,” said Kristina Capiak, Anavex’s vice president of regulatory affairs, in a statement. “Armed with the necessary data from the Phase 2a study to optimally design future trials, we look forward to expanding our development program.”
Anavex Life Sciences Corp., a biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of Alzheimer’s disease, central nervous system diseases, and pain and various cancers. Its lead drug candidates comprise ANAVEX 2-73 and ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), which is in a Phase IIa clinical trial for the treatment of Alzheimer’s disease.
Finally, e-Future Information Technology Inc. (NASDAQ:EFUT), gained 19.70%, and is now trading at $7.58.
eFuture Information Technology, declared that it will release its financial results for the third quarter ended September 30, 2015 on November 20, 2015 after the US market closes.
eFuture Information Technology Inc. provides software and services to retail and consumer goods industries in the People’s Republic of China. The company develops and sells enterprise resource planning software; and provides solutions for distribution, retail, and logistics businesses. It offers software solutions, which comprise foundation solutions for retail administration, point of sale, distribution administration, logistics administration, warehouse administration, vendor payment and control, and loyalty card administration; collaborative solutions for visual SCM and visual process administration systems; and intelligent solutions for business intelligence, brand analysis, supplier relationship administration, and customer relationship administration systems.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.